PLANEGG-MARTINSRIED, Germany--(BUSINESS WIRE)--4SC AG (Frankfurt, Prime Standard: VSC) the German drug discovery and development company, in conjunction with Royal Marsden Hospital in Sutton, England, today announced that it will present Phase I data on 4SC-201, an innovative histone deacetylase (HDAC) inhibitor, at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, USA, from May 29 to June 2, 2009. The Phase I data, generated in advanced solid tumors will form the basis of 4SC's drug development program in oncology.
